EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)

Series type: Joint Reports

Summary

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

Download as PDF

Table of contents

  • Introduction
  • Information collection process
  • Information required by Article 5.2 of the Council Decision
  • Information from the EMA (Article 5.3 of the Council Decision)
  • Conclusion
  • References
Pages: 
15
Price: 
Free
ISBN: 
978-92-9497-206-4
ISSN: 
1977-7868
Pub. DOI: 
10.2810/41095
Catalog Number: 
TD-AS-17-006-EN-N
Loading